Pimavanserin (INN), or pimavanserin tartate (USAN), marketed under the trade name Nuplazid, is a non-dopaminergic atypical antipsychotic developed by Acadia Pharmaceuticals for the treatment of Parkinson's disease psychosis and schizophrenia. Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT2A receptor, with 40-fold selectivity for this site over the 5-HT2C receptor and no significant affinity or activity at the 5-HT2B receptor or dopamine receptors. The drug has met expectations for a Phase III clinical trial for the treatment of Parkinson's disease psychosis, and has completed Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication.

CAS：706779-91-1
中文别名：哌马色林;2-胺基-5-(4-硝基苯磺酰)-噻唑;1-(4-氟苄基)-3-(4-异丁氧基苄基)-1-(1-甲基哌啶-4-基)脲;
英文别名：N-[(4-Fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N\'-[[4-(2-Methylpropoxy)phenyl]Methyl]urea;N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-yl)-N\'-[[4-(2-Methylpropyloxy)phenyl]Methyl]carbaMide;N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\'-(4-(2-methylpropyloxy)phenylmethyl)carbamide;N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N\'-(4-isobutoxybenzyl)carbamide;Unii-jz963p0dik;Pimavamserin;1-[(4-fluorophenyl)Methyl]-1-(1-Methylpiperidin-4-yl)-3-{[4-(2-Methylpropoxy)phenyl]Methyl}urea;1-(4-fluoro-benzyl)-3-(4-isobutoxy-benzyl)-1-(1-methyl-piperidin-4-yl)-urea;N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N\'-(4-(2-methylpropyloxy)phenylmethyl) carbamide;1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea;Nuplazid;
分子式：C25H34FN3O2
分子量：427.555
精确质量：427.264
Psa：44.81
Logp：4.9953

外观与性状：浅黄色或浅橙色固体
密度：1.15±0.1 g/cm3 (计算值)
沸点：604.2±55.0 °C (760 mmHg, 计算值)
熔点：100-103 ºC
闪点：319.222ºC
折射率：1.576
可溶性：甲醇（微溶）
储存条件：冰箱内低温冷藏

危险品标志：Xi